Back to Search
CARLOS BECERRA, M.D.
M.D.
Medical Oncology Physician
NPI: 1235171281IndividualAccepts Medicare
Education
OTHER
Class of 1989
Research & Publications (20)
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
PMID 18525298·Am J Clin Oncol·2008
3-trial
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
PMID 15685835·Oncology (Williston Park)·2004
3-trial
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
PMID 12767075·Int J Cancer·2003
3-trial
Estimation of canine intestinal parasites in Córdoba (Spain) and their risk to public health.
PMID 16971046·Vet Parasitol·2007
7-preclinical
Functional expression of H4 histamine receptor in human natural killer cells, monocytes, and dendritic cells.
PMID 18025238·J Immunol·2007
8-other
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
PMID 17227899·Oncologist·2007
6-review
Computational and experimental analysis identifies Arabidopsis genes specifically expressed during early seed development.
PMID 16504176·BMC Genomics·2006
4-observational
Adverse effects of bevacizumab and their management in solid tumors.
PMID 18632501·Support Cancer Ther·2006
8-other
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
PMID 17007746·Acta Pharmacol Sin·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3410 WORTH ST STE 400
DALLAS, TX 75246 - Phone
- (214) 370-1000
Quick Facts
- NPI
- 1235171281
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile